Similar fecal immunochemical test results in screening and referral colorectal cancer

被引:0
|
作者
Sietze T van Turenhout [1 ]
Leo GM van Rossum [2 ]
Frank A Oort [1 ]
Robert JF Laheij [3 ]
Anne F van Rijn [4 ]
Jochim S Terhaar sive Droste [1 ]
Paul Fockens [4 ]
René WM van der Hulst [5 ]
Anneke A Bouman [6 ]
Jan BMJ Jansen [7 ]
Gerrit A Meijer [8 ]
Evelien Dekker [9 ]
Chris JJ Mulder [10 ]
机构
[1] Department of Gastroenterology and Hepatology, VU University Medical Center,1081 HV Amsterdam, The Netherlands
[2] Department of Epidemiology Biostatistics and HTA, Radboud University Nijmegen Medical Center,6500 HB Nijmegen, The Netherlands
[3] Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center,6500 HB Nijmegen, The Netherlands
[4] Department of Gastroenterology and Hepatology, Academic Medical Center,1105 AZ Amsterdam, The Netherlands  5. Department of Gastroenterology and Hepatology, Kennemer Gasthuis, 2035 RC Haarlem, The Net
关键词
Screening population; Referral cohort; Fecal immunochemical test; Tumor stage distribution; Colorectal cancer;
D O I
暂无
中图分类号
R735.3 [肠肿瘤];
学科分类号
100214 ;
摘要
AIM: To improve the interpretation of fecal immunochemical test (FIT) results in colorectal cancer (CRC) cases from screening and referral cohorts. METHODS: In this comparative observational study, two prospective cohorts of CRC cases were compared. The first cohort was obtained from 10 322 average risk subjects invited for CRC screening with FIT, of which, only subjects with a positive FIT were referred for colonoscopy. The second cohort was obtained from 3637 subjects scheduled for elective colonoscopy with a positive FIT result. The same FIT and positivity threshold (OC sensor; ≥ 50 ng/mL) was used in both cohorts. Colonoscopy was performed in all referral subjects and in FIT positive screening subjects. All CRC cases were selected from both cohorts. Outcome measurements were mean FIT results and FIT scores per tissue tumor stage (T stage). RESULTS: One hundred and eighteen patients with CRC were included in the present study: 28 cases obtained from the screening cohort (64% male; mean age 65 years, SD 6.5) and 90 cases obtained from the referral cohort (58% male; mean age 69 years, SD 9.8). The mean FIT results found were higher in the referral cohort (829 ± 302 ng/mLvs 613 ± 368 ng/mL,P = 0.02). Tissue tumor stage (T stage) distribution was dif-ferent between both populations [screening population: 13 (46%) T1, eight (29%) T2, six (21%) T3, one (4%) T4 carcinoma; referral population: 12 (13%) T1, 22 (24%) T2, 52 (58%) T3, four (4%) T4 carcinoma], and higher T stage was significantly associated with higher FIT results (P < 0.001). Per tumor stage, no significant difference in mean FIT results was observed (screening vs referral: T1 498 ± 382 ng/mL vs 725 ± 374 ng/mL, P = 0.22; T2 787 ± 303 ng/mL vs 794 ± 341 ng/mL, P = 0.79; T3 563 ± 368 ng/mLvs 870 ± 258 ng/mL,P = 0.13; T4 not available). After correction for T stage in logistic regression analysis, no significant differences in mean FIT results were observed between both types of cohorts (P = 0.10). CONCLUSION: Differences in T stage distribution largely explain differences in FIT results between screening and referral cohorts. Therefore, FIT results should be reported according to T stage.
引用
收藏
页码:5397 / 5403
页数:7
相关论文
共 50 条
  • [21] Diagnostic accuracy of fecal immunochemical test in average- and familial-risk colorectal cancer screening
    Cubiella, Joaquin
    Castro, Ines
    Hernandez, Vicent
    Gonzalez-Mao, Carmen
    Rivera, Concepcion
    Iglesias, Felipe
    Teresa Alves, Maria
    Cid, Lucia
    Soto, Santiago
    De-Castro, Luisa
    Vega, Pablo
    Antonio Hermo, Jose
    Macenlle, Ramiro
    Martinez, Alfonso
    Estevez, Pamela
    Cid, Estela
    Herreros-Villanueva, Marta
    Portillo, Isabel
    Bujanda, Luis
    Fernandez-Seara, Javier
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2014, 2 (06) : 522 - 529
  • [22] Making FIT Count: Maximizing Appropriate Use of the Fecal Immunochemical Test for Colorectal Cancer Screening Programs
    Cusumano, Vivy T.
    May, Folasade P.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2020, 35 (06) : 1870 - 1874
  • [23] Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels
    Wilen, Hanna Ribbing
    Blom, Johannes
    Hoijer, Jonas
    Hultcrantz, Rolf
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 (01) : 103 - 112
  • [24] Stable hemoglobin concentration with fecal immunochemical test at high temperatures in a Caribbean colorectal cancer screening program
    Blake, Shacara N.
    Kortlever, Tim L.
    Verbrugge, Sue Ellen
    van Vuuren, Anneke J.
    Dekker, Evelien
    van der Vlugt, Manon
    Hugtenburg, Jacqueline G.
    CLINICA CHIMICA ACTA, 2024, 560
  • [25] Adenoma detection rate and colorectal cancer risk in immunochemical fecal test screening programs
    Antonelli, Giulio
    Battagello, Jessica
    Zorzi, Manuel
    Hassan, Cesare
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 33 - 33
  • [26] Academic hospital staff compliance with a fecal immunochemical test-based colorectal cancer screening program
    Georgia Vlachonikolou
    Paraskevas Gkolfakis
    Athanasios D Sioulas
    Ioannis S Papanikolaou
    Anastasia Melissaratou
    Giannis-Aimant Moustafa
    Eleni Xanthopoulou
    Gerasimos Tsilimidos
    Ioanna Tsironi
    Paraskevas Filippidis
    Chrysoula Malli
    George D Dimitriadis
    Konstantinos Triantafyllou
    World Journal of Gastrointestinal Oncology, 2016, (08) : 629 - 634
  • [27] Academic hospital staff compliance with a fecal immunochemical test-based colorectal cancer screening program
    Vlachonikolou, Georgia
    Gkolfakis, Paraskevas
    Sioulas, Athanasios D.
    Papanikolaou, Ioannis S.
    Melissaratou, Anastasia
    Moustafa, Giannis-Aimant
    Xanthopoulou, Eleni
    Tsilimidos, Gerasimos
    Tsironi, Ioanna
    Filippidis, Paraskevas
    Malli, Chrysoula
    Dimitriadis, George D.
    Triantafyllou, Konstantinos
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 8 (08) : 629 - 634
  • [28] The Role of Fecal mRNA Cyclooxygenase 2 and Fecal Immunochemical Test to Detect Colorectal Cancer
    Saragih, Arlyando Hezron
    Abdullah, Murdani
    Yusra
    Handjari, Diah Rini
    Prabu, Oryza Gryagus
    ADVANCED SCIENCE LETTERS, 2017, 23 (07) : 6950 - 6953
  • [29] Predicting the risk for colorectal cancer with personal characteristics and fecal immunochemical test
    Li, Wen
    Zhao, Li-Zhong
    Ma, Dong-Wang
    Wang, De-Zheng
    Shi, Lei
    Wang, Hong-Lei
    Dong, Mo
    Zhang, Shu-Yi
    Cao, Lei
    Zhang, Wei-Hua
    Zhang, Xi-Peng
    Zhang, Qing-Huai
    Yu, Lin
    Qin, Hai
    Wang, Xi-Mo
    Chen, Sam Li-Sheng
    MEDICINE, 2018, 97 (18)
  • [30] Comparing a fecal immunochemical test and circulating tumor DNA blood test for colorectal cancer screening adherence
    Laven-Law, Geraldine
    Symonds, Erin L.
    Winter, Jean M.
    Chen, Gang
    Flight, Ingrid H.
    Hughes-Barton, Donna
    Wilson, Carlene J.
    Young, Graeme P.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 (07) : 1267 - 1276